Outbreak of Hemolytic Uremic Syndrome Linked to Escherichia Coli of Serotype O104:H4

Outbreak of Hemolytic Uremic Syndrome Linked to Escherichia Coli of Serotype O104:H4 in Bordeaux Urban Area, June 2011: Evaluation of Diagnostic, Prognostic and Pathophysiological Data

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01406288

Acronym

SHU O104 CUB

Enrollment

Registered

2011-08-01

Start date

2011-07-31

Completion date

2012-03-31

Last updated

2012-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Escherichia Coli Infections, Hemolytic-uremic Syndrome

Keywords

hemolytic-uremic syndrome, shiga-toxin-producing E. Coli

Brief summary

The Hemolytic Uremic Syndrome (HUS) in its typical form occurs after a food born infection with a shiga-toxin secreting bacteria, usually Escherichia coli of the O157H7 serotype. An outbreak of bloody diarrhea followed by HUS begun after a collective meal with 120 persons on June 8th, 2011 in Bègles, a city of Bordeaux urban area (CUB). At least 9 patients, 8 adults and 1 child have been involved in this HUS outbreak, E. coli of the O104:H4 serotype being demonstrated in most patients. This outbreak is remarkable by its preponderance in adults and women, its aggressiveness with multiorgan involvement , i.e. the kidneys, brain, liver, pancreas, and skin. Pathophysiology, prognosis, and treatment of typical HUS are poorly defined, particularly in adults who are usually not involved in typical E. coli O157H7 HUS. The aim of the present study is to gain knowledge on these different aspects of the HUS, including response to therapy.

Interventions

OTHERHUS standard coverage care (including in ICU)

HUS standard coverage care : plasmaphereses - eculizumab - Immunoadsorption

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

2 Years to No maximum

Healthy volunteers

Inclusion criteria

* All patients with HUS concomitant to the outbreak linked to E. coli O104:H4

Exclusion criteria

* Patient not willing to participate or to sign informed consent

Design outcomes

Primary

Measure	Time frame	Description
Improve scientific knowledge on epidemic HUS in the context of an outbreak of E. coli O104:H4 HUS in the town of Bègles, urban area of Bordeaux, France	during patient hospitalization	This is an observational propspective study in which all data will be collected on all pertinent aspects of disease, including therapeutic regimens.

Secondary

Measure	Time frame
evaluate efficiency of therapeutic and diagnostic strategies	during patient hospitalization

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026